ATO inhibits tumor growth and angiogenesis of HCC by blocking the paracrine signaling of Ang-1 and Ang-2 through the inhibition of the p-Akt/HIF-1α pathway after IRFA. This evidence concerns the gene AKT1 and hepatocellular carcinoma.